Naperville, IL -- (SBWIRE) -- 10/30/2013 -- Reportstack, provider of premium market research reports announces the addition of Menjugate (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 market report to its offering
Menjugate (Meningococcal Vaccines) - Forecast and Market Analysis to 2022
Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.
Menjugate (Meningococcal Group C -CRM197 Conjugate Vaccine) is the brand name for Novartis MenC conjugate vaccine registered in the EU, Australia, and Brazil. The vaccine was originally developed and marketed by Wyeth (now Pfizer), and Nuron Biotech acquired Meningitec in December 2012.
- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Menjugate including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Menjugate for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Menjugate performance
- Obtain sales forecast for Menjugate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)
To view the table of contents for this market research report please visit